Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | GLA | P06280 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008034 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4EKMT2AGLAHPGD | |
| SCHEMBL1535992 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4EKMT2AGLAHPGD | |
| SCHEMBL29365630 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4EKMT2AGLAHPGD | |
| SCHEMBL7806621 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4EKMT2AGLAHPGD | |
| SCHEMBL29628937 | 0.79 | DHFR (0.53) | ALDH1A1KDM4EKMT2AGLAHPGD | |
| SCHEMBL8891970 | 0.78 | ALDH1A1 (0.50) | ALDH1A1KDM4EKMT2AGLAHPGD | |
| SCHEMBL2590289 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KDM4EKMT2AGLAHPGD | |
| SCHEMBL194326 | 0.76 | ALDH1A1 (0.46) | ALDH1A1KDM4EKMT2AGLAHPGD | |
| SCHEMBL4299906 | 0.75 | ALDH1A1 (0.70) | ALDH1A1KDM4EKMT2AGLAHPGD | |
| SCHEMBL329444 | 0.75 | ALDH1A1 (0.60) | ALDH1A1KDM4EKMT2AGLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378936-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-06-05 | — | — | EP | claimed |
| CN-116969923-A | Heteroaryl amino compounds, methods of preparation and use thereof | 北京鞍石生物科技有限责任公司 | 2023-10-31 | — | — | CN | claimed |
| WO-1997027179-A2 | ANTIRETROVIRAL BASES | NOVARTIS AG (CH) | 1997-07-31 | — | — | WO | claimed |
| EP-4378936-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-116969923-A | Heteroaryl amino compounds, methods of preparation and use thereof | 北京鞍石生物科技有限责任公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-115835751-A | Organic light emitting diode and organic light emitting device including the same | 乐金显示有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-106957317-B | Novel pyrazole derivatives | 持田制药株式会社 | 2019-12-31 | — | — | CN | disclosed |
| US-9777000-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20160347751-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-12-01 | — | — | US | disclosed |
| US-9458157-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9453015-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-1487444-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | Fujisawa Deutschland GmbH (DE) | 2004-12-22 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| WO-2003080054-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | FUJISAWA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | WO | disclosed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-6239108-B1 | Cell adhesion inhibitors | BIOGEN, INC. | 2001-05-29 | — | — | US | disclosed |
| WO-1997027179-A2 | ANTIRETROVIRAL BASES | NOVARTIS AG (CH) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347751-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | ALDH1A1 387/4885KDM4E 1309/4885KMT2A 2932/4885 |
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | ALDH1A1 228/4885KDM4E 1370/4885KMT2A 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.